Kidney Cancer: Highlights from 2006 eulogo1

By: and Francesco Montorsilowast

Published online: 01 July 2007

Keywords: Angiogenesis inhibitors, Cryoablation, Partial nephrectomy, Radiofrequency ablation, Renal cell carcinoma, Sorafenib, Sunitinib, Temsirolimus

Abstract Full Text Full Text PDF (534 KB)



This paper communicates the most relevant findings on renal cell carcinoma (RCC) presented at the 2006 annual meetings of the European Association of Urology (EAU), American Urological Association (AUA), and the American Society of Clinical Oncology (ASCO) and discussed during a closed meeting in Marbella in October 2006. Furthermore, the attendees’ opinions on a representative clinical case study were assessed using interactive voting and experts in the field commented on the results.


The most relevant new findings were selected by urologic experts in the field of RCC.


With regard to treatment of localised RCC, partial nephrectomy remains relatively uncommon, even for small tumours (<4cm). In addition, studies presented on the minimally invasive techniques, cryoablation and radiofrequency ablation, are clearly promising; however, more data are needed to further evaluate their long-term oncologic outcomes. With regard to advanced RCC, important studies were presented that further evaluated the efficacy and safety of several angiogenesis inhibitors. Sunitinib was superior to interferon-α (IFN-α) as first-line treatment for patients with advanced clear-cell RCC. Sorafenib significantly prolonged the progression-free survival compared to placebo in patients previously treated for advanced RCC. Monotherapy with temsirolimus significantly increased the overall survival time in poor-risk patients compared to IFN-α alone or combination therapy with temsirolimus and IFN-α.


Relevant new data on surgical and minimally invasive treatment of localised disease and promising systemic treatments for advanced RCC were presented at the 2006 urologic/oncologic meetings.

Take Home Message

This paper reviews recent data on kidney cancer, which were discussed during a closed meeting, including partial nephrectomy, minimally invasive techniques, such as cryoablation and radiofrequency ablation, and potential systemic treatments for advanced and metastatic disease (sunitinib, temsirolimus, and sorafenib).

Keywords: Angiogenesis inhibitors, Cryoablation, Partial nephrectomy, Radiofrequency ablation, Renal cell carcinoma, Sorafenib, Sunitinib, Temsirolimus.

1. Introduction

Cancers of the renal parenchyma, also known as renal cell carcinomas (RCCs), account for just under 2% of all cancers worldwide. Although RCC is a relatively rare cancer, its incidence, as well as its associated mortality rates, have been increasing over the past 50 yr [1], [2], [3], and [4]. A significant part of this apparent increase is believed to result from the wider application of imaging techniques such as ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), leading to a rise in the number of incidentally diagnosed RCCs [4]. However, data from American studies showed that, besides an increase in presymptomatic localised tumours, there has also been an increase in locally advanced and distant metastatic RCCs, suggesting that advanced imaging techniques are not the sole contributors to the rapidly increasing incidence [5], [6], and [7].

Prognosis for patients with RCC varies considerably depending on the stage of disease at diagnosis. According to the Surveillance Epidemiology and End Results (SEER) database, about 70–80% of the patients present with localised disease, which is associated with an 89.9% 5-yr survival rate. However, the 5-yr survival rate in patients with locally advanced disease drops to 61%, whereas patients with distant metastatic disease have only a 9% 5-yr survival rate [8].

These poor survival rates indicate that current therapies are insufficient, especially for patients with advanced disease characteristics. Over the past few years, however, increasing knowledge about the molecular and genetic basis of RCC has stimulated the development of novel and more targeted treatment strategies. Furthermore, advances in surgical techniques may favour a more conservative treatment for patients with localised disease.

This paper comprises the latest highlights on kidney cancer presented at the 2006 urologic and oncologic annual meetings of the European Association of Urology (EAU) in Paris, the American Urological Association (AUA) in Atlanta, and the American Society of Clinical Oncology (ASCO) also in Atlanta. A selection of abstracts from these congresses were discussed at a closed expert meeting “New Horizons in Urology” in Marbella. In addition, participants at this meeting were engaged in an interactive voting procedure to assess their opinions on a representative clinical case study and experts in RCC commented on the results.

2. Treatment of localised disease

Treatment approaches for RCC depend on disease stage at presentation. The standard treatment for patients who are diagnosed with local RCC and who have two functioning kidneys is radical nephrectomy (RN). However, advances in surgical and imaging techniques over the past several years have created the possibility of applying nephron-sparing surgery or minimally invasive treatment strategies as alternatives to invasive RN [8].

2.1. Partial nephrectomy

Partial nephrectomy (PN) was first advocated in patients with a single kidney or a nonfunctioning contralateral kidney or in patients with or at risk for bilateral RCC. However, the current EAU guidelines on RCC also recommend PN for patients with a solitary tumour <4cm [8]. Although these guidelines propose that easy-operable tumours of 4–7cm can be treated with PN, this should be addressed cautiously because it has been shown in a study presented at this year's EAU meeting that tumour size is positively correlated with aggressiveness even in tumours <4cm. This study evaluated the pathologic stage of 287 solid kidney tumours ≤4cm. It was shown that advanced stage (≥ pT3a) was found in 2, 12, and 35 of RCC tumours ≤2cm, 2.1–3cm, and 3.1–4cm, respectively (Fig. 1) [9].


Fig. 1 The size of renal cell carcinomas (RCCs) correlates with advanced stage (≥ pT3a) [9].

Even though it has been demonstrated that PN in patients with a tumour <4cm provides recurrence-free and long-term survival rates similar to those observed after RN, data from a retrospective study presented at the AUA meeting in 2006 indicated that urologists are still hesitant to perform PN [10] and [11]. Using the population-based SEER data, it was shown that of the 14,647 patients surgically treated for primary RCC7cm between 1988 and 2001, 90.4% underwent RN, whereas only 9.6% were treated with PN. For tumours ≤7cm, a progressive increase in the use of PN was seen between 1988 (4.6%) and 2001 (17.6%; p<0.01); nevertheless, PN remained an uncommon treatment strategy, even for small tumours. Among patients with tumours <2cm, 14% were treated with PN in 1988–1989 versus 42% in 2000–2001 and for tumours 2–4cm, 5% and 20% underwent PN, respectively (p<0.01; Fig. 2). Notwithstanding this increased frequency of PN over the two decades, its use remains relatively uncommon, despite its equivalent cancer control and the advantageous functional outcomes associated with the preservation of the renal parenchyma [11].


Fig. 2 Although, a gradual increase in the percentage of partial nephrectomy (PN) has been observed in 1988–1989 and 2000–2001, it remains a relatively uncommon procedure, even in small size renal cell carcinomas (RCCs) [11].

2.2. Minimally invasive techniques

New and progressive minimally invasive techniques such as laparoscopic cryoablation (LCA) or radiofrequency ablation (RFA) are emerging as alternative therapies for the treatment of small RCCs, especially for patients who are poor candidates for surgical interventions. These procedures consist of the insertion of a probe into the tumour using real-time imaging guidance by ultrasonography, CT, or MRI, and then destroying the tumour with cold (LCA) or heat (RFA) [12]. Although these techniques have the disadvantage compared to traditional surgery in that histopathologic confirmation of complete tumour resection with clear margins is not possible, a great deal of attention was paid to both of these minimally invasive techniques at this year's urologic meetings.

2.2.1. LCA

LCA is an emerging technique for a select group of patients who preferentially have small (<4cm), solid, peripheral renal tumours that do not involve the central collecting system [8]. Although several small studies with median follow-up reported promising oncologic outcomes and low complication rates after renal LCA, multicentre studies with long-term follow-up of treated patients are necessary to further validate the efficacy and safety of this new procedure [13], [14], [15], and [16].

A study presented at AUA 2006 annual meeting assessed the long-term oncologic outcomes in patients treated with LCA between September 1997 and September 2005 [17]. Sixty patients treated with LCA completed at least 5 yr of follow-up (median: 72 mo) that consisted of MRI on postoperative day 1, at 3, 6, and 12 mo, and annually from then on. Furthermore, a needle biopsy was performed in conjunction with the 6-mo scan. The initial indication for treatment was a solitary sporadic RCC in 73% of the patients, with a mean tumour size of 2.3cm (range: 1–4.5cm). Three patients (6.7%) developed a local tumour recurrence; two of them remained disease-free on dialysis following nephrectomy. The other patient, however, died 10 mo after nephrectomy on dialysis with no evidence of further disease. Given that the cancer-specific 5-yr survival rate was 100% along with the low incidence of recurrences, it was concluded that LCA is feasible in those patients with small, solitary sporadic tumours [17]. Although the cancer-specific 5-yr survival rate in this study was considered reassuring by the urologic experts, the remark was made that this outcome mainly relies on the skills of the surgeon. It was suggested that they should be proficient in laparoscopic surgery prior to engaging themselves in performing LCA.

Even though the former study may support the use of LCA in a select group of patients, a matched-cohort study by O’Malley and colleagues comparing laparoscopic PN (LPN) and LCA did not favour the use of LCA over LPN for the treatment of small peripheral tumours [18]. In this study, 15 patients who had LCA between May 2003 and July 2005 were compared with an age- and tumour size-matched cohort of 15 patients from a pre-existing database of 104 patients who underwent LPN between July 2002 and July 2005. Surgical outcomes between the two groups were similar; only the LPN group had a significantly longer operating time (p<0.001) and a higher estimated blood loss (p=0.007) compared to the LCA group (Fig. 3). There were no recurrences recorded in either of the two groups and both had a similar mean follow-up period of 9.8 and 11.9 mo, respectively. It was concluded that, especially in elderly patients with comorbidities precluding blood loss or renal ischaemia, LCA is a good choice for treatment of small RCCs. Still, in experienced hands, LPN remains the preferred option and should be considered as the definitive treatment of small, sporadic renal tumours [18].


Fig. 3 Both operation time and estimated blood loss are significantly higher for laparoscopic partial nephrectomy (LPN) compared to laparoscopic cryoablation (LCA) [18].

At the closed meeting in Marbella, however, some concerns were expressed regarding this study. It was emphasised that it was a retrospective, small-scale study with a short-term follow-up period and that rather long-term data from a head-to-head prospective large-scale study are needed to bring more insights on whether or not LPN should be favoured above LCA.

2.2.2. RFA

Another minimally invasive technique that is currently being evaluated is RFA, which has gained more popularity in recent years. Although RFA was initially proposed for patients unfit for (laparoscopic) surgery due to a poor performance status (American Society of Anesthesiologists [ASA] score of 3 or 4), serious comorbidities, minor renal function, or high-risk for developing additional RCCs, a study presented at the AUA 2006 annual meeting assessed this technique in healthy ASA 1 and 2 patients [8], [19], and [20]. Thirty-seven patients with a mean age of 57 yr (range: 20–84 yr) and a mean tumour size of 2.2cm (range: 1–4cm) were treated with either open or laparoscopic RFA. The follow-up period was at least 12 mo with a mean follow-up of 27 mo (range: 12–48 mo). During the postoperative follow-up, no incomplete ablations were detected. Only one patient developed a recurrence at 24 mo. This patient underwent salvage RN, which revealed RCC on final pathology, and is without disease 1 yr later. Four minor complications were reported: three patients with self-limiting neuralgia/paresthesia secondarily related to ablation and one with asymptomatic hydrocalyx detected 18 mo after RFA treatment.

Although these and prior results show that treatment of small RCCs with RFA is feasible and safe in both ASA 1 or 2 and ASA 3 or 4 patients, clearly more data from larger-scale studies with long-term follow-up are needed to further validate these results [20], [21], and [22]. It has been suggested that for long-term evaluation of the ablative properties and completeness, more adequate long-term oncologic outcomes should be assessed and preferentially compared with PN as a standard [23].

In this respect, a study, presented at the AUA 2006 annual meeting, compared intermediate outcomes of patients diagnosed with cT1a renal tumours who were treated with PN or RFA [24]. Of all patients treated for cT1a RCC between July 1994 and May 2005, 141 patients were selected for this study because they did not present with bilateral synchronous or metachronous tumours, metastatic disease, or hereditary RCC. From these, 53 (37.6%) underwent open or laparoscopic PN, whereas the remaining 88 (62.4%) had either percutaneous or laparoscopic cryoablation. The mean age was 56.5 yr (range: 32–79 yr) in the PN group and 62.6 yr (range: 18–85 yr) in the RFA group, and mean follow-up periods were 3.4 yr (range: 1.3–8.8 yr) and 1.4 yr (range: 6 wk to 3.5 yr), respectively. There were four incomplete ablations and three recurrences in the RFA group. Of these, four had a successful re-ablation, one died of heart failure, and two underwent nephrectomy, revealing residual RCC in one and benign tumour in the other. In the PN group, on the other hand, there were two patients with recurrences of whom one had a new enhancing renal mass and the other was diagnosed with advanced RCC that was treated with nephrectomy. The recurrence-free probability at 3 yr was 97.5%±0.83% for the PN group and 95.7%±0.71% for the RFA group (p=0.102) [24]. It was concluded that PN and RFA have a comparable 3-yr outcome for treatment of cT1a renal tumours; however, the remark was made that to obtain straightforward results on this issue, a head-to-head comparative and randomised long-term study should be performed.

Overall, it can be stated that RN remains the gold standard treatment for localised disease. However, during recent years, there has been a growing tendency towards nephron-sparing and less invasive laparoscopic surgery because these procedures clearly improve the patient's postoperative quality of life. Given the rising importance of laparoscopic surgery for the treatment of RCC, it was indicated at the “New Horizons in Urology” meeting in Marbella that new residents in urology should be proficient in laparoscopic surgery on completion of their training. With regard to minimally invasive techniques such as LCA and RFA, so far, no studies are available evaluating the long-term oncologic outcomes of these rather new procedures. However, it is believed that these techniques are promising and efforts should be undertaken for further optimalisation.

During the closed expert meeting “New Horizons in Urology” held in 2006, the participants were engaged in an interactive voting procedure to assess their treatment preference on a representative case study suggestive of kidney cancer. The results were discussed and experts in the field of RRC offered comments.

A 61-yr-old woman with hypertension and type 2 diabetes presented to the physician complaining of left flank pain for the last 2 wk. An ultrasound examination showed a peripheral renal mass of approximately 3.5cm. This finding was further confirmed by CT, which clearly showed a 3.5-cm mass on the periphery, but going into the parenchyma. Preoperative tests showed that she had a normal renal function, normal blood analysis, and no signs of distant lesions on radiographic examination. Additionally, a bone scan was negative. Regarding this issue, the brief comment was made by the expert panel that for small renal masses, like the one presented here, a bone scan is not a routine procedure.

With this background information in mind, the participants from the closed meeting were asked to choose a treatment strategy through interactive voting. The results from this voting procedure are shown in Fig. 4. Forty percent of the participants chose open PN, whereas a surprising 30% went for its laparoscopic counterpart. The remaining persons chose RN, either open or laparoscopic (Fig. 4).


Fig. 4 Results from interactive voting indicate that partial nephrectomy (PN), either open or laparoscopic, is the favoured treatment option for the given case (details are outlined in the text). Surprisingly, open or laparoscopic radical nephrectomy (RN) is still a frequently chosen treatment strategy. None of the participants chose another minimally invasive (MI) technique as treatment option.

Thus, the majority of the attendees decided on performing an open PN and this procedure was actually performed on the patient. However, the experts reflected on the fact that a large proportion of the urologists voted for LPN. Although a progressive shift from open to laparoscopic surgery has been seen over the past few years, performing LPN remains a challenging procedure due to the risk of converting PN into RN because of technical issues. Therefore, training of new residents should focus on this issue and it was advocated by the author that on completion of their residency, urologists should be able to perform laparoscopic surgery. Finally, the remark was made that still 30% of the attendees to the closed meeting opted for RN. Given the data currently available on treatment of small renal masses, this was regarded as over-treatment by some of the experts.

3. Treatment of advanced and metastatic disease

To date, treatment of metastatic RCC with surgical intervention or immunotherapy has been largely unsuccessful. In patients with limited metastases, nephrectomy and resection of metastatic lesions may be a suitable therapy. Generally, however, the cancer is too widespread and the standard treatment for those patients is immunotherapy with interferon-α (IFN-α) or interleukin 2 (IL-2). Unfortunately, IFN-α or IL-2 administered as a single agent only achieves response rates of 8–26% and 7–23%, respectively [25]. These poor outcomes have emphasised the need for new and more effective treatment strategies.

Over the past several years, the understanding of the molecular and genetic basis of RCC has led to the development of new agents for the treatment of metastatic RCC. Although RCC has several histologic subtypes, 70–80% of all tumours contain clear-cell RCC (ccRCC) morphology of which both sporadic and hereditary forms are associated with mutations in the van Hippel-Lindau (VHL) tumour suppressor gene. Loss of the VHL protein function eventually leads to overexpression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), both of which promote tumour angiogenesis and by consequence contribute to the hypervascularisation of RCC [26]. Therefore, novel developments in the treatment of RCC aimed at targeting the VEGF and PDGF pathways with the intention to reverse the physiologic consequences of losing the VHL protein function. In this respect, several new drugs have been developed of which sunitinib, sorafenib, and temsirolimus were extensively discussed at this year's urologic and oncologic congresses.

3.1. Sunitinib

Sunitinib, also known as SU11248, is a small molecule receptor tyrosine kinase inhibitor (TKI) with both direct antiproliferative and antiangiogenic properties by targeting VEGF, PDGF, KIT, and FLT3 tyrosine kinases [27]. Recently, promising results were obtained in two multicentre, phase 2 trials that assessed the clinical activity and safety of sunitinib as second-line therapy for patients with metastatic RCC who progressed after one prior cytokine therapy [28] and [29]. In summary, 34–40% of the patients treated with sunitinib achieved a partial response and an additional 27–29% of the patients demonstrated stable disease for ≥3 mo. The median progression-free survival was 8.3–8.7 mo.

A phase 3 clinical trial of sunitinib versus INF-α as a first-line treatment of metastatic RCC was presented at the ASCO 2006 annual meeting [30] and has recently been published [31]. Between August 2004 and October 2005, 750 patients with metastatic ccRCC were randomised in a 1:1 ratio to receive sunitinib (6-wk cycles: 4 wk 50mg orally once daily followed by 2 wk off) or IFN-α (6-wk cycles: subcutaneous injection of 9 million units [MU] given three times weekly). The objective response rate was significantly higher for sunitinib compared to IFN-α (p<0.000001; Fig. 5). Moreover, also a higher median progression-free survival rate was observed in patients receiving sunitinib (47.3 wk) versus those receiving IFN-α (24.9 wk) with a hazard ratio of 0.394 (p<0.000001). Concerning safety outcomes, only 8% of the patients taking sunitinib withdrew from the study due to adverse events, whereas this was the case for 13% of the patients taking IFN-α[30]. Although this study suggests that sunitinib is superior to IFN-α as first-line treatment for patients with metastatic ccRCC, still more data are needed to further confirm these results.


Fig. 5 The objective response rate in patients with advanced renal cell carcinoma is higher after sunitinib treatment compared with interferon-α (IFN-α) treatment [30].

3.2. Sorafenib

Sorafenib, formerly known as BAY 43-9006, is a novel bi-aryl urea initially developed as a specific inhibitor of Raf kinase. More detailed analysis showed that sorafenib also has significant activity against other TKIs involved in tumour progression and neoangiogenesis including VEGFR2 VEGFR3, PDGFR-β, FLT3, and c-KIT [32]. So far, two phase 2 studies have shown the antitumour activity of sorafenib and at the EAU 2006 annual meeting results were presented from a double-blind, placebo-controlled phase 3 study [33], [34], and [35]. These results were recently published [36]. A total of 905 patients diagnosed with advanced ccRCC in whom one prior systemic treatment course had failed were randomised to receive continuous oral sorafenib twice daily or placebo added with the best supportive care. First interim analysis of 769 patients demonstrated that the median progression-free survival time was 24 wk for sorafenib compared to 12 wk for placebo, with a hazard ratio of 0.44 (p<0.000001). In addition, 75% of the patients taking sorafenib had not progressed after 3 mo of treatment versus 43% of those on placebo. Therefore, it was concluded that sorafenib significantly prolongs the progression-free survival compared to placebo in patients previously treated for advanced RCC [35].

3.3. Temsirolimus

Temsirolimus (CCI 779) is a specific inhibitor of mammalian target of rapamycin (mTOR), a serine/threonine protein kinase that, through its role as key regulator of the cell cycle, presented itself as a potential target for antitumour therapy [37]. In a phase 2 clinical trial by Atkins et al, 7% of the 111 patients with advanced RCC who were assigned to this single-agent study on temsirolimus obtained an objective response and a minor response was observed in 26% of the patients [38]. The efficacy and safety of temsirolimus was further addressed in a three-arm, randomised, phase 3 study that was presented at the ASCO 2006 annual meeting [39]. In this study, 626 patients with advanced RCC with no prior systemic therapy were randomised at a 1:1:1 ratio to arm 1 (IFN-α up to 18 MU subcutaneously twice/wk; n=207), arm 2 (temsirolimus 25mg intravenously once/wk; n=209), or arm 3 (temsirolimus 15mg intravenously once/wk+IFN-α 6 MU subcutaneously twice/wk; n=210). Fig. 6 shows the median overall survival rate for the 3 groups based on data from the preliminary interim analysis. Compared to IFN-α treatment alone, temsirolimus was associated with a significant 49.3% increase in the overall survival time (p=0.0069; Fig. 6), whereas this was not the case with the combination treatment. It was concluded that monotherapy with temsirolimus significantly increases the overall survival time in poor-risk patients with advanced RCC compared with IFN-α, whereas this was not observed after treatment with combination therapy (temsirolimus+IFN-α) [39].


Fig. 6 Temsirolimus (Temsr) treatment of patients with advanced renal cell carcinoma generates a significant increase in median survival compared to interferon-α (IFN-α) treatment, whereas no significant increase was observed with the combination therapy (Temsr+IFN-α) [39].

Next to sorafenib, sunitinib, and temsirolimus, the monoclonal antibody bevacizumab has been evaluated for its use as second-line therapy in metastatic RCC as well. Although the results that have been gathered on these new drugs are promising, especially because they are more effective than cytokines in the treatment of metastatic RCC, clearly additional data are needed to further validate and confirm these results. Additionally, more research is needed to further improve the current drugs and to develop new therapeutic agents because, so far, no complete response is achieved with antiangiogenic drugs.

4. Conclusions

At the key urologic and oncologic congresses of 2006, many interesting and promising new data were presented. Although an increasing body of evidence supports the implementation of PN as a first-line treatment for localised disease, SEER data from the United States show that PN remains relatively uncommon, even in small RCCs (<4cm). However, urologists performing PN should keep in mind that even in these small tumours, the size of the RCC is positively correlated with advanced stage (≥ pT3a), which implicates a thorough selection of possible candidates.

A great deal of interest was also devoted to minimally invasive techniques. A large study with a 5-yr follow-up period demonstrated that LCA treatment was associated with a high cancer-specific 5-yr survival rate. However, it was suggested that, to achieve this kind of outcome, physicians should be proficient in performing laparoscopic surgery. Therefore, new residents should be qualified to master this technique on completion of their residency, not only to perform LCA, but also for RN and PN. Another study suggested that even though LCA is a good treatment option for small RCCs, especially in elderly people unfit for surgery, LPN should remain the preferred option as definitive treatment of small, sporadic renal tumours. Although RFA is normally reserved for patients at risk for surgery, a 2-yr follow-up study showed that this technique is also safe and feasible in patients with ASA status 1 or 2. Furthermore, a comparison was made between PN and RFA for treatment of cT1a RCC, which showed that both techniques have a comparable 3-yr outcome. Although these data on minimally invasive techniques seem promising, more large-scale, long-term data are needed to further confirm them.

Driven by the poor outcomes of surgical and cytokine-based treatment of advanced RCC and the progress made in elucidating the molecular and genetic basis of RCC, several new agents have been developed including sunitinib, sorafenib, and temsirolimus. It was shown that sunitinib is superior to IFN-α as first-line treatment for patients with advanced ccRCC. Furthermore, a large-scale phase 2 study demonstrated that sorafenib significantly prolongs the progression-free survival compared to placebo in patients previously treated for advanced RCC. Finally, it was demonstrated that single-agent temsirolimus, and not the combination therapy temsirolimus+IFN-α, significantly increases the overall survival compared to IFN-α as first-line treatment in poor-risk patients with advanced RCC. However, more research is needed, not only to further confirm these results, but also to further optimise these new drugs and to develop new therapeutic agents to achieve complete remission in patients with metastatic RCC in the future.

Conflicts of interest

Francesco Montorsi is a paid consultant for Pfizer, Bayer, GSK, AMS, Pierre Fabre and Eli Lilly.


  • [1] http://www-dep iarc fr/. Accessed 2006.
  • [2] http://www seer cancer gov/. Accessed 2006.
  • [3] A. Jemal, R. Siegel, E. Ward, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130 Crossref.
  • [4] A.J. Pantuck, A. Zisman, A.S. Belldegrun. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-1623
  • [5] W.H. Chow, S.S. Devesa, J.L. Warren, J.F. Fraumeni Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-1631 Crossref.
  • [6] L.M. Hock, J. Lynch, K.C. Balaji. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol. 2002;167:57-60
  • [7] S.R. Mindrup, J.S. Pierre, L. Dahmoush, B.R. Konety. The prevalence of renal cell carcinoma diagnosed at autopsy. BJU Int. 2005;95:31-33 Crossref.
  • [8] B. Ljungberg, D.C. Hanbury, M.A. Kuczyk, et al. Guidelines on renal cell carcinoma. EAU guidelines. 2006;:1-26
  • [9] M. Remzi, H.C. Klingler, M. Öszoy, et al. Renal tumours between 3 and 4cm show significantly more aggressive parameters than tumours equal or less than 3cm. An analysis of 287 renal tumours ≤4cm. Eur Urol Suppl. 2006;5:107 (abstract no. 339) Abstract, Full-text, PDF, Crossref.
  • [10] R.G. Uzzo, A.C. Novick. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol. 2001;166:6-18
  • [11] D.C. Miller, J.M. Hollingsworth, K.S. Hafez, S. Daignault, B.K. Hollenbeck, A. Arbor. Partial nephrectomy for small renal masses: an emerging quality of care concern?. J Urol. 2006;175:229 (abstract no. 708)
  • [12] E.J. Trabulsi, P. Kalra, L.G. Gomella. New approaches to the minimally invasive treatment of kidney tumors. Cancer J. 2005;11:57-63 Crossref.
  • [13] A. Cestari, G. Guazzoni, V. dell’Acqua, et al. Laparoscopic cryoablation of solid renal masses: intermediate term followup. J Urol. 2004;172:1267-1270 Crossref.
  • [14] D.I. Lee, D.E. McGinnis, R. Feld, S.E. Strup. Retroperitoneal laparoscopic cryoablation of small renal tumors: intermediate results. Urology. 2003;61:83-88 Crossref.
  • [15] T.D. Moon, F.T. Lee Jr., S.P. Hedican, P. Lowry, S.Y. Nakada. Laparoscopic cryoablation under sonographic guidance for the treatment of small renal tumors. J Endourol. 2004;18:436-440 Crossref.
  • [16] R.B. Nadler, S.C. Kim, J.N. Rubenstein, R.L. Yap, S.C. Campbell, H.M. User. Laparoscopic renal cryosurgery: the Northwestern experience. J Urol. 2003;170:1121-1125 Crossref.
  • [17] N.J. Hegarty, I.S. Gill, J.H. Kaouk, et al. Renal cryoablation: 5 year outcomes. J Urol. 2006;175:351 (abstract no. 1091)
  • [18] R.L. O’Malley, A.D. Berger, J.A. Kanofsky, C.K. Phillips, M. Stifelman, S.S. Taneja. A matched-cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses. BJU Int. 2007;99:395-398 Crossref.
  • [19] R.J. Zagoria. Imaging-guided radiofrequency ablation of renal masses. Radiographics. 2004;24(suppl 1):S59-S71 Crossref.
  • [20] J.M. Stern, S. Park, J.K. Anderson, et al. Kidney tumor radiofrequency ablation: experience in ASA I and ASA II patients. J Urol. 2006;175:27 (abstract no. 81)
  • [21] A.A. Wagner, S.B. Solomon, L.M. Su. Treatment of renal tumors with radiofrequency ablation. J Endourol. 2005;19:643-652
  • [22] S. Park, J.K. Anderson, E.D. Matsumoto, Y. Lotan, S. Josephs, J.A. Cadeddu. Radiofrequency ablation of renal tumors: intermediate-term results. J Endourol. 2006;20:569-573 Crossref.
  • [23] M. Aron, I.S. Gill. Minimally invasive nephron-sparing surgery (MINSS) for renal tumours. Part II: probe ablative therapy. Eur Urol. 2007;51:348-357 Abstract, Full-text, PDF, Crossref.
  • [24] J.M. Stern, R.S. Svatek, S. Park, J.K. Anderson, Y. Lotan, J.A. Cadeddu. Intermediate follow-up comparison between partial nephrectomy and radio frequency ablation in T1A renal tumors. J Urol. 2006;175:16 (abstract no. 46)
  • [25] R.H. Weiss, P.Y. Lin. Kidney cancer: identification of novel targets for therapy. Kidney Int. 2006;69:224-232 Crossref.
  • [26] P.H. Patel, R.S. Chaganti, R.J. Motzer. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer. 2006;94:614-619
  • [27] D.B. Mendel, A.D. Laird, X. Xin, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337
  • [28] R.J. Motzer, B.I. Rini, R.M. Bukowski, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524 Crossref.
  • [29] R.J. Motzer, M.D. Michaelson, B.G. Redman, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24 Crossref.
  • [30] R.J. Motzer, T.E. Hutson, P. Tomczak, et al. Phase III randomized trial of sunitnib malate (SU1 1248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2006;24:2 (abstract no. LBA3)
  • [31] R.J. Motzer, T.E. Hutson, P. Tomczak, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124 Crossref.
  • [32] S.M. Wilhelm, C. Carter, L. Tang, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109 Crossref.
  • [33] T. Ahmad, T. Eisen. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10:6388S-6392S Crossref.
  • [34] M.J. Ratain, T. Eisen, W.M. Stadler, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512 Crossref.
  • [35] B. Escudier, C. Szczylik, T. Eisen, et al. Randomised phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur Urol Suppl. 2006;5:287 (abstract no. 1058) Crossref.
  • [36] B. Escudier, T. Eisen, W.M. Stadler, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134 Crossref.
  • [37] J.P. Dutcher. Mammalian target of rapamycin inhibition. Clin Cancer Res. 2004;10:6382s-6387s Crossref.
  • [38] M.B. Atkins, M. Hidalgo, W.M. Stadler, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918 Crossref.
  • [39] G. Hudes, M. Carducci, P. Tomczak, et al. A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alfa (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor-prognosis patients with advanced renal cell carcinoma. J Clin Oncol. 2006;24:2 (abstract no. LBA4)


Department of Urology, Università Vita Salute San Raffaele, Via Olgettina 60, 20132 Milan, Italy

lowast Tel. +39 02 26437423; Fax: +39 02 264 37 298. Please visit to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.